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THE  GENERATION  AND  REGULATION  OF  LYMPHOCYTE 
POPULATIONS 
Evidence from Differentiative Induction Systems in Vitro* 
BY MARGRIT P.  SCHEID, GIDEON GOLDSTEIN,$ AND EDWARD A.  BOYSE§ 
(From the Memorial Sloan-Kettering Cancer Center, New York 10021) 
As the cells that are programmed to generate the various sets of immunocom- 
petent  lymphocytes progress along their several  pathways they pass through 
discrete  phases  of  differentiation  that  can  be  recognized  by  the  selective 
expression of cell surface components. Detailed investigation of the nature and 
mechanisms  of these  differentiative  steps  has  been  much  facilitated  by  the 
development  of  short-term  assays  in  which  some  of these  phenotypes  are 
induced in vitro (1-4). We present here an account of our findings with induction 
assays that monitor an early step in T-cell differentiation,  marked by acquisi- 
tion of the surface component Thy-1, and two steps in B-cell differentiation, the 
first marked by acquisition of complement receptors (CR) 1 (5) and the second by 
acquisition of the surface component PC (plasma cell antigen)  (6). 
Materials and Methods 
Congenic  a-Thy-l.2 Antiserum  [A-Thy-l.1  x  AKR-H-2  b anti-A strain  leukemia ASL1].  For 
use in induction assays this antiserum was preabsorbed with Thy-l.1 thymocytes and leukemia 
cells until negative in cytotoxicity assays with congenic Thy-l.1 thymoeytes.  Resultant  specific 
titers against congenic Thy-l.2 thymocytes were >1:2,000.  Without this preabsorption,  unidenti- 
fied contaminant  antibody  (possibly murine leukemia virus-related) can give erroneous positive 
results.  Anti-Thy-l.2 antiserum  of lower specific titer is inadequate  for induction  assays.  (The 
same  requirements  for  preabsorption  and  high  specific titer  apply  equally  to the  alternative 
antiserum  a-TL, which has given results similar to a-Thy-1 in all respects  [7].) 
PC Antisera and PC Induction Assay.  The same considerations of titer and specificity apply 
to a-PC serum  (DBA/2  x  B6)F1  anti-BALB/c myeloma MOPC-70A (6}, in PC induction assays. 
This antiserum was preabsorbed with thymus and spleen of PC  strains of mice, including B6, the 
resulting  specific cytotoxicity titer  being  1:64 against  MOPC-70A cells with guinea  pig serum 
(GPSI as the source of complement),  and  1:32 or 1:64 against  induced  Peyer's patch cells, with 
rabbit C. We found Peyer's patches to be the richest source of PC-inducible Ig~:CR÷:PC  cells, but 
their proportion is still too low for a satisfactory induction assay. Therefore we used Peyer's patch 
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cells from mice stimulated with Corynebacterium  parvum  (1 mg per animal, i.p., 5-7 days before 
harvest), cleared of dead cells by a  two-step bovine serum albumin (BSA) gradient. This yielded 
25-30c~  PC-inducible  cells  (scored  with  preabsorbed  a-PC  serum  diluted  1:16,  after  2.5-3  h 
incubation). 
Other Antisera.  Rabbit  anti-mouse  immunoglobulin  (R-~-MIg)  consisted  of immunoabsor- 
bent-purified a-MIgM  combined with immunoabsorbent-purified a-F(ab):  of MIgG  (4),  used  in 
cytotoxicity procedures at a  final concentration of 0.1  mg/ml.  Purified  19S  fraction of rabbit  a- 
sheep erythrocytes (SRBC) (Cordis Laboratories, Inc., Miami, Fla. ) diluted 1:100 was used in the 
CR assay. 
Complement (C).  Ample rabbit C  is crucial to cytoxicity assays for induction of cell-surface 
markers.  GPS  is generally  inadequate.  Rabbits were  screened  for low natural cytotoxicity  for 
thymocytes and high C activity in a system (a-Lyt-2.2) which demands a high level of C. For each 
pool of C, usually one or two rabbits were selected from 20-30 pretested rabbits. 
Thymopoietin (8) and ubiquitin (3) were lyophilized'in 1-1zg lots, with 100  ~g BSA to reduce 
loss from adsorption to glass, and dissolved in RMPI-1640 immediately before use. 
Pharmacological  Agents.  cAMP (adenosine 3':5' monophosphoric acid); DBcAMP (N~O~-dibu- 
tyryl-adenosine  3':5'  monophosphoric  acid);  theophylline; DL-isoproterenol;  L-isoproterenol;  DL- 
propranolol; epinephrine (L-epinephrine); imidazole, carbachol (carbamylcholine chloride); cyclo- 
heximide  (Sigma  Chemical  Co.,  St.  Louis,  Mo.).  We  thank  Dr.  M.  Weksler  (Cornell  Medical 
College)  for  providing  L-propranolol,  Dr.  J.  Pike  (Upjohn  Co.,  Kalamazoo,  Mich./  for  PGE1 
(prostaglandin El),  Dr.  C.  Henney (Johns Hopkins University) for choleratoxin Icholera-entero- 
toxin)  and  8-bromo-cGMP  (8-bromo-cyclic guanosine  monophosphate),  Dr.  G.  Renoux  (Tours- 
Cedex,  France) for poly A:U (polyadenylic-polyuridylic acid),  and Dr.  C.  Galanos (Freiburg) for 
lipopolysaccharide (endotoxin) and lipid A. 
Ervthrocyte  Antibody  Complement Complex  (EAC) Indicator Cells.  SRBC  were washed and 
suspended  in medium  199  (5%); an equal volume of rabbit a-SRBC  added;  incubated  (37°C,  15 
min); washed three times and resuspended (5%); added to an equal volume of normal AKR mouse 
serum  (diluted 1:5); further incubated (37°C,  45 min~; washed twice,  and resuspended  in RPMI- 
1640 (5%). 
Densi(v-Gradient  Centrifugation  to Fractionate  the  Spleen  Cell Population  for Enrichment  of 
Inducible  Cells  (illustrated  in  Fig.  1).  5-10  ×  107  washed  spleen  cells  (85-95c7c viablel  were 
pelleted in a  5-ml Beckman cellulose nitrate tube (150 g).  The supornate was removed,  and the 
walls of the tube dried. The cells were suspended in 1 ml 35% BSA (Pathocyte 5, lot 21, 22; Miles 
Laboratories Inc., Miles Research Products, Elkhart, Ind.), overlaid with four 1-ml layers of BSA 
(29:26:23:10%)  as shown in Fig.  1,  and the gradient was centrifuged (Beckman model L; SW50.1 
rotor;  13,000  rpm;  30  rain).  Each  layer  was  aspirated  in  turn  through  each  interface  to  the 
midpoint of the next layer, diluted at least 1:15 with RPMI-1640, and the cells washed twice before 
use  in  induction assays.  Some  lots of BSA were  unsuitable because they contained  >1  ~g/ml 
endotoxin, itself an inducer (9),  and Ficoll proved unsatisfactory because some lots had inducing 
activity. 
The  Standard  Cell  Population  for  Common  use  in  Thy-1  and  CR  Induction  Assays.  The 
standard cell population used as the common source of cells for prothymocyte and pro-CR ~ cell 
assays  was  the  combined  B  and  C  layers  indicated  by  the  arrows  in  Fig.  1.  To  avoid  high 
backgrounds of pre-existing CR  + cells in the CR induction assay, we used spleen from nu/nu mice, 
which if healthy have fewer CR * cells than nu/+  and other phenotypically normal mice (Dr.  M. 
C.  Gelfand, personal communication; and M.  P.  Scheid, unpublished observations). We used nu/ 
nu  mice of our own colony  (bred on a  BALB/c background and maintained under conventional 
conditions), aged 1-2 mo.  Spleen cells of normal mice, depleted of CR* cells by sedimentation as 
rosettes with EAC  (5),  were used with equal success for preparing the standard cell population 
when nu/nu mice were not available. 
General Description  of the Induction Assays.  The cells (1-5  ×  10  T cells/ml RPMI-1640) were 
distributed  into 5-ml  plastic tissue  culture  tubes  (BioQuest,  BBL  &  Falcon  Products,  Becton, 
Dickinson  &  Co.,  Cockeysville,  Md.).  An equal  volume of inducer  (in RPMI-1640)was  added. 
After incubation for 10 min at 37°C  in a  waterbath (to equilibriate temperature) the tubes were 
placed in a  humidified 5% CO2 incubator at 37°C for 2-2.5  h.  Afterwards the cells were washed 
twice in RPMI-1640,  resuspended  in medium  199  for cytotoxicity  assays,  or  RPMI-1640  for CR 
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The CR* phenotype for assay of B cells (5} was scored as follows: 0.3 ml EAC (0.5~ suspension) 
was added to 0.3 ml of the induced cell suspension (2  x  10~/ml), and EDTA to 0.01 M, in a Beem 
plastic electron-microscopy capsule IErnest F. Fullam, Inc., Schenectady, N.Y.). The suspension 
was shaken at 37°C in a waterbath and then placed on ice; (the capsules can be held at 4°C over- 
night without change in the readings}. A rosette was defined as a cell binding ->3 EAC. At least 
300  cells from  each  tube  were counted,  and  the  proportion of rosetted cells expressed as  the 
percentage of total nucleated cells (rosetted plus nonrosetted). Controls for which due allowance 
was  made  in  calculating  CR-specific complex  rosetting  and  induction  indices  included:  (al 
erythrocyte antibody substituted for EAC, and I b} omission of the cells tested for induction. 
Controls  for  Background  Induction  and  for  Loss  of Surface  Markers  during  Induction 
Assays.  Each assay was controlled for the following three factors: (a)  marker-positive cells in 
the starting population: this was estimated by cytotoxicity assays on the standard cell population 
immediately before induction assay  (Control A).  (b) Induction by contaminants: contaminants 
such as endotoxin in some lots of BSA, encountered during fractionation of spleen cells, produce a 
background of induced cells after 2 h of culture. This was estimated by control cultures to which 
no inducer was added IControl B).  Control B should equal Control A  if there is no background 
induction.  (c)  Loss of surface markers: the proportion of cells that register FcR, Ig, or CR, but 
never Thy-1 or PC, may fall in controls at 37°C without added inducer IControl B). This does not 
occur at 0°C.  Hence Control C  (for induction assays of FcR, Ig,  and CR) which is the same as 
Control B but at 0°C. Any test in which controls A, B, and C differed significantly was discarded. 
Calculation  of Percentages of Cells Induced.  The formula for all three markers (Thy-1, CR, 
PC)  was  (a  -  b)/(100  -  b)  x  100, where a  =  percent marker-positive cells in the presence of 
inducer, and b  =  percent marker-positive cells in the absence of inducer. The values of b  in a 
series of 12 representative tests were 8 (SEM -+ 5) for the prothymocyte assay, 13  (SEM +- 5) for 
the pro-CR  ÷ assay, and generally <5 for the PC assay. 
Elimination of Thy-1 ÷  and Ig ~ Cell Populations.  Washed spleen cells were suspended (2 x  107/ 
ml) in a-Thy-l.2 (1:50) or a-MIg (1:100); incubated at 4°C for 30 min; washed once; suspended at 
the original concentration in rabbit serum (C) diluted 1:15; incubated (shaken) for 30 min at 37°C 
in  a  waterbath;  counted  in  trypan  blue;  layered  on  a  two-step  (10-35%)  BSA  gradient;  and 
centrifuged to separate the dead cells.  Cytotoxicity assays of the viable cells recovered at the 
interface showed  >90%  to  be Thy-1-  or  Ig  -~,  respectively. A  control in  which antiserum was 
omitted was always run, to confirm that the pool of C in use still gave negligible cytolysis. 
Results 
I.  Enrichment  of  Precursor  Cells  by  Density  Gradient  Centrifugation; 
Distribution  of Cell  Types  in  the  Standard  Gradients.  The term prothymo- 
cytes (10) is used for the cells in bone marrow and spleen which lack the T-cell 
surface antigens Thy I:TL:Lyt but express them when induced to differentiate 
in vitro (1). 
The term  pro-CR  ÷ cells  refers to cells of the  B-lymphocyte lineage,  in the 
spleen and to a lesser extent in bone marrow, which do not express CR but do so 
when induced to differentiate in vitro (granulocytes and macrophages are CR  ÷, 
but form CR rosettes only in the presence of divalent cations [11] which EDTA 
excludes in our CR assay). 
Fig. 1 shows the BSA gradient used and (for A strain spleen) the distribution 
profiles of: (a)  prothymocytes, (b) pre-existing Thy-1  ÷ cells,  (c)  pro-CR  ÷ cells, 
and (d) pre-existing CR  ÷ cells. The profiles of all four cell typos, shown on the 
right in Fig.  1,  are different from one another,  implying that prothymocytes 
and pro-CR  ÷ cells are different inducible populations. 
II.  The Kinetics ofT-Cell and CR ÷  B-Cell Induction.  Demonstrable induc- 
tion of Thy-1 and TL expression requires 2 h  (1/.  In a  preparatory study we 
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Fro.  1.  Distribution of spleen cell types in the standard BSA gradient. 
* Prothymocytes: phenotype TL  :Thy  1  ,  inducible to  express all  thymocyte surfac~ 
markers; § Pro-CR* cells: B-lineage cells inducible to express CR; phenotype Ig÷:Ia÷:CR-; 
$ T cells: phenotype TL  :Thy l+:Lyt ÷.  IICR  ÷ cells: Ig*:Ia*:CR  +.  Layers B and C combined 
generally from nu/nu mice, are referred to as the standard cell population for inductio~ 
(see Materials and Methods). The data shown here are averages for 5-10 x  10 7 spleen cell~ 
from A strain mice aged 2-3 mo, on the standard gradient (volume of each of the five laye~ 
=  1 mlL 
from mice aged 2-3 mo; a longer induction period may be required for cells f°om 
younger donors. 
Induction does not require presence of inducer throughout the 2-h perioE  10 
min,  the shortest time tested,  sufficed for near-maximal  registration  of inluc- 
tion (at 2 h) by ubiquitin in both assays and by thymopoietin selectively inthe 
T-cell assay. Thus the time required for manifestation of the induced phenoiype 
is much longer than  the time required for initiation  by either  inducer.  Tlese 
data suggest initiation  by a  surface ligand which triggers intermediary ev,  nts 
leading to phenotypic expression.  Mediation by cAMP is suggested by rep)rts 
that  its addition causes induction  and that  pharmacological  interference vith 
cAMP metabolism blocks induction,  in both assays (2). We tested this furlher 
by adding imidazole during  induction,  in a  concentration  at which imidazde's 
known  action  is to  decrease  cellular  cAMP and  increase  cGMP,  probabl3 by 
activating cellular cAMP phosphodiesterase (12). Imidazole inhibited induaion 
in both assays completely when added  10 min  after the inducer,  and partially 
when  added  up to  30  min  later  (Table  I).  Thus  the  critical  period for cAMP 
action appears to be the first 30 min of the induction process. 
III.  Metabolic  Requirement  for  Induction.  Prothymocyte  induction  re- 
quires  cell  metabolism;  it  is  prevented  by lowering  the  temperature  and by 
inhibitors of transcription  and translation  (13).  The same is true of pro-CR B- 
cell induction;  we find no CR induction  at 4°C.  In both assays,  cycloheximde 
blocked  induction  completely  at  concentrations  of 2.5  and  10  ~tg/ml  (wlich 
reduce cellular  incorporation  of [3H]leucine by about 95%  [13]),  and  partially 
at 0.1 ~g/ml (25% inhibition of [3H]leucine uptake [13]). 
IV.  Further Evidence  that Prothymocytes and Pro-CR + Cells are Disc'ete 
Populations.  Fig. 2 shows: (a) that thymopoietin, throughout its entire raage 
of effective concentration,  generates only thymocytes (panels 1 and 2) whe,eas 
ubiquitin  generates  both  thymocytes  and  CR  ÷  cells  (panels  3  and  4).  (b) 
Induction  by ubiquitin  is  prevented  by propranolol  (10  -5  M),  a  fl-adrene'gic 
blocking  agent  (14),  in  both  assays  (panels  3  and  4),  whereas  inductiol  of 
prothymocytes by thymopoietin is not prevented by propranolol  (panel 1). 
If there  were  a  single  uniform  immediate  precursor  population  capable  of 
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TABLE  I 
Suppression of Prothymocyte and Pro-CR ÷  B-Cell Induction by Imidazole 
1731 
Imidazole (10 -T M) added after: 
Cells induced % 
Ubiquitin  Pro-thymocyte  Pro-CR + cell as- 
(0.1 ~g/ml)  0  10  30  60  90  assay  say 
min 
1st  2nd  1st  2nd 
Exp.  Exp.  Exp.  Exp. 
None  0  0  0  0 
(Standard)  (Standard) 
Present  15  20  16  22 
None  +  -1  -4  -3  -3 
Present  +  -  8*  -  5  -  3  -  4 
Present  +  -  6  -  2  2  -  1 
Present  +  11  15  6  17 
Present  +  16  24  10  15 
Present  +  10  19  15  17 
* High negative indices presumably reflect imidazole's suppression of the usual low background 
of cells induced in controls without an added inducer. 
100 
60 
20 
100 
v~ 
60 
20 
-(9 
PRO-THYMOCYTE  PRO-CR ÷  CELL 
ASSAY  ASSAY 
(Thy-1)  (CR) 
v 
f  ° 
10  .3  10  .2  I0 "1  1  -®  T~ 
10 .4  10 .2  1 
10  -3  10  .2  10  "1  1 
r~  r~ 
J  Propra nolol~// 
10 .4  10  .2  1 
Concentration  of  Inducer  (~g/ml) 
Fro.  2.  Effects of propranolol  (10 -5 M) on induction by thymopoietin (panels 1 and 2) and 
ubiquitin  (panels  3  and  4)  in  dual  induction  assays with  the  standard  cell  population. 
(Mean values for four separate sets.) 
* Because  the  proportion  of  cells  induced  varies  somewhat  according  to  the  cell 
preparations used in different experiments, the data shown are standardized as percent of 
maximal induction in the positive control  (no inhibitor; optimal concentration of inducer) 
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TABLE  II 
Inductive Selectivity  of Thymopoietin and of Ubiquitin, as Indicated by Sequential 
Induction Assays 
First induction  Second induction 
Cells induced %  Cells induced %* 
Inducer  Inducer 
(0.1 ~g/ml)  Pro-thymocyte  Pro-CR + cells  (0.1 tzg/ml)  Pro-thymo-  Pro-CR + 
assay  assay  cyte assay  cell assay 
Thymopoietin  15 ± 7  <2  Ubiquitin  <2  40 +_ 4 
Ubiquitin  16 ± 5  23 +_ 3  Ubiquitin  <2  35 _+ 5 
None  0  0  Ubiquitin  12 ± 3  25 -2_ 5 
(Standard)  (Standard) 
* Mean ± SEM for four experiments. 
TABLE  III 
Prothymocyte Induction Assays with R-c~-MIg-Depleted Cell Populations 
Step 2: 
Step 1:  Induction 
Cytolysis  Inducer: 
Cells induced %* 
Pro-thymocyte  Pro-CR+  cell as- 
assay  say 
R-a-MIg + C 
None  0  0 
CStandard)  (Standard) 
Thymopoietin (0.5 izg/ml)  26 ± 3  5 ± 3 
Endotoxin (30 tzg/ml)  21 ± 4  -1 ± 5 
C Alone (control) 
None  0  0 
(Standard)  (  Standard/ 
Thymopoietin (0.5 ~tg/ml)  22 ± 3  -3 z  2 
Endotoxin (30 tzg/ml)  19 _+ 6  20 ± 5 
The  starting population for  step  1 was  unfractionated spleen cells,  after  which  the 
standard cell population was prepared as usual. 
* Mean ± SEM for four experiments. 
by thymopoietin, which produces only thymocytes, should leave no cells capable 
of subsequently being induced to form CR  ÷ cells. 
Table II  shows  data  for experiments in which the  standard cell population 
was treated with thymopoietin or with ubiquitin (first induction) and then with 
a-Thy 1 +  C to eliminate the thymocytes induced. The cells were then subjected 
to a  second induction, with ubiquitin. There was no further yield of T cells. The 
higher proportion of CR  ÷ cells after the second induction is due to the relative 
enrichment  of CR  +  cells  caused  by  elimination of the  T  cells  after  the  first 
induction. This result is not compatible with generation of thymocytes and CR  + 
cells from the same immediate precursor pool. 
Table III shows data for experiments in which pro-CR  ÷ cells, which are Ig  ÷, 
were eliminated from the standard cell population by cytolysis with R-a-MIg + 
C.  Subsequent  induction revealed  no  loss  of inducible prothymocytes.  These 
data  further  support  the  conclusion that  prothymocytes  and pro-CR  +  B  cells 
are distinct populations. 
V.  Evidence  That  There  are Different  Receptors  for  Thymopoietin  and for MARGRIT  P.  SCHEID,  GIDEON  GOLDSTEIN,  AND  EDWARD  A.  BOYSE 
TABLE IV 
Receptor Specificity: Effect of  Excess Ubiquitin  on Sensitivity to 
Induction by Ubiquitin  and by Thymopoietin 
Inducer* 
Cells induced %$ 
Pro-thymocyte  Pro-CR ÷ cell 
assay  assay 
Thymopoietin  18 -+ 5  1 -+ 3 
Ubiquitin  1 -  3  1 -  2 
Thymopoietin +  Ubiquitin  15 +_ 7  1 -+ 4 
DBcAMP (1 mM) +  Ubiquitin  13  +- 5  10 -+ 2 
* In  a  concentration  of 0.5  ~g/ml  for  thymopoietin,  and  200  ~g/ml 
(predetermined induction-inhibitory concentration) for ubiquitin. 
$ Mean +- SEM of three experiments. 
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Ubiquitin.  The  observations  that  thymopoietin  induces  only prothymocytes 
whereas  ubiquitin  also induces  pro-CR*  B  cells,  and  that  propranolol,  which 
prevents  binding  of/3-adrenergic  agonists  (14),  blocks induction  by ubiquitin 
but  not  by thymopoietin  (Fig.  2),  suggest  that  the  two  inducers  react  with 
different receptors. Furthermore,  high concentrations of ubiquitin do not induce 
prothymocytes or pro-CR  ÷ cells (Table IV, line 2), but this block does not hinder 
induction  of prothymocytes by thymopoietin  (line  3),  nor of prothymocytes or 
pro-CR  * cells by DBcAMP (line 4). 
VI.  Pharmacology of Induction.  The evidence above points to two distinct 
precursor  populations  which  are  precommitted  to  the  thymocyte  and  B-cell 
phenotypes, respectively, and to a common intermediary mechanism,  probably 
involving cAMP. Pharmacological evidence supports this interpretation. 
CYCLIC NUCLEOTIDES.  Because cAMP and DBcAMP are inducers (2), cGMP 
should have counter-effects if lymphocyte induction conforms to known cAMP- 
mediated systems (14).  Panels  1 and  2 in  Fig.  3 give dose-response curves for 
DBcAMP and show no induction by cGMP (8-bromo cGMP) in either assay over 
the  same  entire  range  of concentrations.  But  cGMP prevented  induction  by 
ubiquitin in both assays when added 10 rain beforehand (panels 3 and 4), and so 
did carbachol  (panels  3 and  4),  an  acetylcholine analog which raises  cellular 
levels ofcGMP in tymphocytes (16, 17). 
PHARMACOLOGICAL  AGENTS  AFFECTING  CYCLIC  NUCLEOTIDE  PHOSPHODIESTER  o 
ASE (PDE) ACTIVITY.  Imidazole activates PDE and lowers the ratio  of  cAMP  to 
cGMP  in lymphocytes (12).  We tested theophylline and imidazole with optimal 
and suboptimal concentrations  of both thymopoietin and ubiquitin. Theophyl- 
line (which at the concentration  used, 2 × 10  -3 M, had no measurable inductive 
effect)  enhanced the activity  of  suboptimal concentrations of  both thymopoietin 
and  ubiquitin, but suppressed  induction  by optimal  concentrations  of both 
inducers. This suppression  is predictable from the dose-response  curves for 
cAMP  (Fig.  3, panels 1 and 2) which show inhibitiofl  of  its  own inductive action 
at high concentration. We also  found that inclusion of  cAMP  with optimal and 
suboptimal concentrations of  either thymopoietin or ubiquitin reproduced these 
effects  of theophylline. In contrast to theophylline, which augments induction, 
imidazole  (10  -7 M)  suppressed  induction  over the entire response  range  of 1734  THE  GENERATION  AND  REGULATION  OF  LYMPHOCYTE  POPULATIONS 
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Fla.  3.  Cyclic nucleotides. The dose-response curves for induction by DBcAMP and cAMP 
(panels 1 and 2) show inhibition at high concentrations. There is no induction by cGMP (8- 
bromo-cGMP)  at  any concentration  (panels  1  and  2),  but cGMP  (10 -3 M),  and carbachol 
(10  s M), inhibit induction by ubiquitin if added 10 min beforehand (panels 3 and 4).  (Mean 
values of four separate tests.) 
effective concentrations of thymopoietin or ubiquitin. (In higher concentrations, 
imidazole itself is an inducer, probably for reasons other than its influence on 
cAMP PDE [12].) 
PHARMACOLOGICAL  AGENTS  ACTIVATING  ADENYLATE  CYCLASE:  CHOLERATOXIN 
AND  ADRENERGIC  COMPOUNDS  (Fig. 4).  Choleratoxin and fl-adrenergic agents 
have been characterized pharmacologically as effective stimulators of adenylate 
cyclase in  nearly every tissue tested,  including lymphocytes (14, 15,  17,  20). 
Both are inducers in both our assays. Choleratoxin gave maximal induction of 
Thy-1  + cells at a concentration of 1 /~g/ml (panel 1) and ofCR  ÷ cells at 0.01/~g/ 
ml  (panel  2).  In  both  assays  induction  by  choleratoxin  was  prevented  by 
imidazole (10 _7 M) added 10 min before the inducer, whereas theophylline (10 -:~ 
M) enhanced induction by suboptimal concentrations of choleratoxin. 
The adrenergic agent epinephrine (panels 3 and 4) gave maximal induction of 
both Thy-1  ÷ and CR  ÷ cells at a concentration of 10 _4 M.  Both inductions were 
inhibited  by  incubation  (for  10  min)  with  propranolol  (10  5  M)  before  the 
addition of epinephrine; whereas in both assays phentolamine (an a-adrenergic 
blocking agent),  at  the  same  concentration and  under  the  same  conditions, 
enhanced induction by suboptimal concentrations of epinephrine, and reduced 
induction by optimal concentrations of epinephrine. This suggests that the /3- 
receptor, but not the a-receptor,  serves for induction in both assays, and that MARGRIT  P.  SCHEID,  GIDEON  GOLDSTEIN,  AND  EDWARD  A.  BOYSE 
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FIG.  4.  Induction by three activators of adenylate cyclase: choleratoxin, epinephrine, and 
L-isoproterenol.  The  pharmacological "data  shown  conform  to  the  interpretation  that 
activation  of adenylate cyclase leads to induction  regardless  of which adenylate-cyclase- 
linked receptor is engaged. Thus induction by choleratoxin was inhibited by imidazole (10  -7 
M) and enhanced by theophylline (10  -3 M) (panels 1 and 2).  Induction by epinephrine was 
inhibited by propranolol (10  -5 M) and enhanced by phentolamine (10  -5 M) (panels 3 and 4). 
Induction  of L-isoproterenol  was  inhibited by  L-propranolol  (10  -5  M)  rather than  by  D- 
propranolol  (10  -5 M) (panels 5 and 6).  * Data standardized as percent maximal induction 
(see footnote to Fig.  2).  (Mean values for three to four tests.) 
1735 
effects  of epinephrine  mediated  by  a-adrenergic  receptors,  known  in  other 
systems (18),  antagonize induction. 
L-isoproterenol,  a  selective  fl-adrenergic  agonist  (18,  19)  was  inductive  in 
both  assays  (panels  5  and  6).  L-propranolol  (10 -s  M)  completely  inhibited 
induction by L-isoproterenol, in concentrations up to 10 -3 M, in both assays.  By 
contrast,  D-propranolol  (10 -5  M),  the  dextrorotatory  d-(+)  isomer,  did  not 
significantly affect prothymocyte induction by L-isoproterenol and only partially 
inhibited induction ofpro-CR  ÷ cells by L-isoproterenol. This suggests that under 
the conditions of our assays the observed effect of propranolol is predominantly 
receptor-specific  and  is  not  due  to  non-specific  membrane  effects or  to  PDE 
activation (18). THE  GENERATION  AND  REGULATION  OF  LYMPHOCYTE  POPULATIONS 
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Fro.  5.  Induction by endotoxin, poly A:U and PGE1. The pharmacological data shown 
conform to the interpretation that induction by these three agents also involves a  cAMP- 
dependent mechanism. (Concentrations of imidazole and theophylline as in Fig. 4.).* Data 
standardized as percent maximal induction (see footnote to Fig. 2). (Mean values for four to 
five tests. ) 
(d)  TESTS WITH OTHER INDUCING AGENTS (Fig.  5).  Endotoxin (panels 1 and 
2)  caused  induction in  both assays,  maximal at  20  i~g/ml  and  less at  higher 
concentrations;  (concentrations above  100  ~g/ml  were  toxic).  Induction  was 
fully inhibited by imidazole (10  -~ M),  and was enhanced by theophylline (10  .3 
M).  Lipid  A  gave  similar  results.  Poly  A:U  (panels  3  and  4)  gave  optimal 
induction at  a  concentration of 10-"-10  -3  ~g/ml,  both  inductions being  fully 
inhibited by imidazole (10  7 M). 
Prostaglandin PGE1  (panels 5 and  6),  which is linked to adenylate cyclase 
activation  in  various  systems  (18),  including  mouse  lymphocytes (20),  gave 
maximal induction of prothymocytes at a  concentration of 10 .8  M  and of pro- 
CR  +  B  cells  at  10  -1°  M.  Induction  was  inhibited  by  imidazole  (10  .7  M). 
Theophylline  (10  .3  M)  enhanced  induction  by  suboptimal  concentrations of 
PGE1, and inhibited induction by optimal or higher concentrations. 
VII.  Features of Late B-CeU Differentiation: The PC +  Phenotype.  PC is the MARGRIT  P.  SCHEID,  GIDEON  GOLDSTEIN~  AND  EDWARD  A.  BOYSE 
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FIG. 6.  Cyclic  nucleotides: dose-response  curves for induction of PC expression  by cAMP 
(DBcAMP) and cGMP (8-bromo-cGMP)  on Peyer's patch cells. Note: (a) induction  by cGMP 
at lower concentrations  is inhibited at higher concentrations, and (b) there is no induction 
by cAMP throughout the range of concentrations tested. (Mean values of four tests.) For 
B6-PC+: cGMP O, cAMP C); for B6 cells (PC- congenic  control): cGMP A, cAMP Ll. 
last of the known surface markers expressed during sequential B-cell differen- 
tiation  (6).  The  penultimate  B-cell  population,  required  for  assaying  PC 
induction, is Ig+:CR+:PC -.  (We find that this population contains cells that are 
not immediately PC-inducible, presumably either because they have not com- 
pleted an intermediate differentiative step or because they belong to a  subset 
committed to a  different terminal program.) The inducible population for the 
PC system was Peyer's patch cells prepared from mice treated with C. parvum. 
(A)  CYCLIC NUCLEOTIDES.  In  contrast  to  early  T-  and  B-cell  induction 
(Section VI,  above),  the  terminal  phenotype PC  was  induced by cGMP,  not 
cAMP.  The dose-response relations (Fig.  6)  show inhibition of induction with 
high concentrations of cGMP, as was the case with cAMP in early T- and B-cell 
inductions  (Fig.  3).  Similarly cAMP  inhibited  induction  of PC  by cGMP,  as 
cGMP inhibited cAMP-mediated early T- and B-cell induction (Fig. 3). 
(S)  PHARMACOLOGY.  If PC-induction is mediated by cGMP, the acetylcho- 
line analog carbachol should act in this system as an inducer rather than an 
inhibitor (which it is in early T- and B-cell induction assays [(Fig. 3,  panels 3 
and 4]). Fig. 7 indicates that this is so. 
(C)  THYMOPOIETIN.  The particular importance of thymopoietin is its claim 
to be a  selective inducer of T-cell differentiation in the dual assay  (see above, 
and  reference 8).  We  therefore paid  much  attention to  its  action  in  the  PC 
induction assay,  especially because we  had  seen  that  thymopoietin partially 
inhibits  CR  ÷  B-cell  induction  by  cAMP  or  ubiquitin  (data  not  shown),  and 
totally  inhibits  induction  of Ia  (21).  As  Fig.  7  shows,  a  concentration  of 
thymopoietin that is optimal for T-cell induction (Fig.  2) completely inhibited 
induction of PC by carbachol. A possible explanation is that thymopoietin is an 
inducer of PC,  and  that  its  ostensible  suppression  of induction by carbachol 
might be attributed to high-dose inhibition (thymopoietin plus carbachol) which 1738  THE  GENERATION  AND  REGULATION  OF  LYMPHOCYTE  POPULATIONS 
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FIG.  8.  Dose-response  data  for  the  effects  of  thymopoietin  on  carbachol-induced  PC 
expression  (upper  panel),  and  on  carbachol-induced  reduction  of CR  expression  (lower 
panel). These data illustrate that thymopoietin neither induced the expression of PC nor 
diminished the expression of CR,  but suppressed both these effects of carbachol.  (Mean 
values of three to eight tests. ) 
is documented for other inducers (Figs.  4 and 5).  But this is not so,  because 
thymopoietin should then enhance PC induction by a suboptimal concentration 
of carbachol,  which  it  does  not  (Fig.  7).  We  confirmed  this  by  assaying 
thymopoietin, over a wide range of concentrations, both alone and in combina- 
tion  with  an  optimal  concentration of carbachol  (10 -6  M),  for  its  effects on 
induction of PC expression. The upper panel of Fig. 8 shows that thymopoietin 
did not induce PC expression at any concentration tested, and that at no point 
did  thymopoietin have  any  effect other  than  inhibition of PC  induction by 
carbachol. The lower panel of Fig. 8, which refers to concomitant assays for CR 
expression with the same Peyer's patch cell suspension, shows that thymopoie- 
tin alone had no effect on the expression of CR, but that it prevented the fall in MARGRIT  P.  SCHEID,  GIDEON  GOLDSTEIN,  AND  EDWARD  A.  BOYSE  1739 
proportion  of CR  ÷ cells that  is characteristic  of carbachol.  We think  it  likely 
that  PC  expression  and  CR  reduction  are  inversely  correlated  phenotypic 
changes affecting one cell set as it differentiates (though this wants proof). But 
regardless of mechanism  these results  signify that receptors for thymopoietin 
are present on Ig+:CR÷:PC - cells. 
Discussion 
We judged CR, scored in the presence of EDTA, to be the most unequivocal 
routine marker for early B cells, and PC the obvious choice for late B cells. For 
T cells, Thy-1 is the best routine early marker.  There is no well-authenticated 
late immunogenetic marker, comparable to PC, for T cells. But there are useful 
data  on  regulation  of  T-cell  functions,  to  represent  late  phases  of  T-cell 
differentiation  (20,  22,  23;  reviewed  in  24,  25),  analogous  to  data  for  B-cell 
functions (26). 
The principle of the dual assay,  in which the induction  of two different cell 
populations is observed simultaneously,  has proved invaluable.  It has allowed 
an explanation of why an assortment of agents,  many seeming physiologically 
incongruous  and  with  varied  pharmacological  actions,  can  induce  prothymo- 
cytes in vitro.  It is now amply substantiated  that prothymocytes and homolo- 
gous  cell  sets  are  preprogrammed  for  particular  phenotypes,  and  that  only 
thymopoietin,  among the variety of prothymocyte-inducing agents tested,  acts 
selectively to induce this particular committed cell set. 
The  application  of dual  assays in other induction  systems now reveals that 
thymopoietin probably has a more comprehensive role in lymphocyte regulation 
than  was  at  first  supposed.  Thymopoietin's  selective  inductive  action  might 
have been explained by restriction of thymopoietin receptors to the prothymo- 
cyte. Evidently this is not so. The ability ofthymopoietin to inhibit induction of 
PC (and Ia [21]) completely, and of CR partially  (data not included),  is no less 
striking  than  its  selective  induction  of prothymocytes.  Thus  thymopoietin 
receptors are evidently present on B  cells also, though presumably geared  in 
this case to a  biochemical circuit that inhibits rather than initiates induction. 
Ubiquitin is a  nonselective inducer which evidently engages a  different recep- 
tor,  doubtless  with  its  own  biochemical  linkage,  which  accords  with  other 
experiments in which we have found that ubiquitin can override the inhibition 
of CR induction produced by thymopoietin. 
Can all these facts relating to initiation and inhibition of induction be plausi- 
bly related to a general scheme of differential regulation by intracellular cyclic 
nucleotides? 
First,  induction  of Thy-1  and  of CR can  be  viewed  as  early  steps  in  the 
differentiation of T  and  B cells, respectively, and both are evidently linked to 
cAMP. Secondly, induction of T-cell functions (24, 25), and induction of PC (and 
of B-cell functions; reviewed in 26), can be viewed as late steps in the differentia- 
tion of T and B cells, respectively, and these evidently are linked to cGMP. This 
conforms  to  a  scheme  in  which  the  exogenous cyclic nucleotides  (which  are 
inducers in their own right),  and similarly the non-specific agents which affect 
levels of intracellular  cyclic nucleotides,  have contrasting effects on the early 
and  late  differentiative  steps referred to,  and  make no distinction  between T 
cells and B cells. Thymopoietin on the other hand has opposite effects on T and 1740  THE  GENERATION  AND  REGULATION  OF  LYMPHOCYTE  POPULATIONS 
B-cell differentiative steps, both early and late.'-' 
We do not infer that  the  nonselective induction  observed in dual  assays in 
vitro has no physiological counterpart  in vivo. On the contrary, this may be a 
pointer to regulators which are necessary to govern lymphocyte populations as 
a  whole in  vivo.  Possibly the  serum factor facteur thymique  serique  (27,  28), 
which  has  properties  similar  to  ubiquitin  in  vitro,  including  sensitivity  to 
inhibition  by adrenergic  blocking  agents  (29),  could  qualify  for  such  a  role. 
Thymopoietin,  in  this  frame  of reference,  plays  the  part  of  a  differential 
regulator of lymphocyte sub-populations. 
Differential regulation of lymphocyte sub-populations by thymopoietin can be 
considered  in  terms  that  are  familiar  in  the  context  of  hormone-receptor 
interactions  (Sonenberg and Schneider; 30) and which include -  (a) degradation 
of the hormone into inductive and other fragments, at the plasma membrane or 
in  the  cytoplasm,  (b)  alternative  modes of coupling  of the  receptor to one or 
another effector mechanism  in the plasma membrane,  and  (c) ensuing activa- 
tion of particular  effector mechanisms and intervention  of second messengers. 
There  are good precedents,  especially in neurotransmission,  for the produc- 
tion of contrasting effects on cellular cAMP and cGMP by the same agent acting 
on  cells  of different  sets  (31,  32).  Ontogeny  in  the  lymphoid  system  (and 
doubtless  generally)  requires  the  balanced  output  and  inter-regulation  of 
multiple  cell  sets  that  emanate  from  a  common  stem  set  and  that  become 
separately but coordinately programmed for cooperative functions. Thymopoie- 
tin,  with its reciprocal effects on facets of T  and B  lymphocyte differentiation 
that depend on cyclic nucleotides, appears well fitted for the role of differential 
regulator,  and this  affords the most plausible explanation  for the inclusion of 
thymopoietin receptors in the phenotypes of different classes of lymphocyte. 
Summary 
Results with a  dual assay, for the induction  of Thy-1 ÷ T cells and of CR  ÷ B 
cells from marker-negative  precursors, confirm that thymopoietin is at present 
the  only  known  selective  inducer  of prothymocytes.  In  contrast,  various  in- 
ducers, including ubiquitin, are active in both assays. Pharmacological evidence 
indicates that there are different cellular receptors for ubiquitin and thymopoie- 
tin. 
Prothymocytes and pro-CR  ÷ B cells compose two distinct populations in bone 
marrow  and  spleen;  their  distribution  in  density  gradients  is  different,  and 
elimination of either population enriches the other proportionately. 
2 Measurements  of cellular  cAMP  in  the  standard  cell  population  used  for  induction  have 
shown significant elevation with nonselective inducers (poly A:U, endotoxin, ubiquitin) but not 
so  far  with  thymopoietin  (R.  G.  Coffey,  M.  P.  Scheid,  and  J.  W.  Hadden,  unpublished 
observations). The reason for this may be purely technical, reflecting the smaller number of cells 
induced by thymopoietin. Because only limited enrichment of the prothymocyte population is as 
yet feasible, elevation of cAMP induced selectively in prothymocytes by thymopoietin may be too 
small to measure  under present conditions of testing.  We are investigating the use of a-Lyb-2 
sera to eliminate B cells tin which we assume cAMP to be elevated by the nonselective inducers) 
and thus achieve adequate enrichment for prothymocytes. Indications that thymopoietin elevates 
cGMP in cell populations rich in mature peripheral T cells (23) conform to the argument developed 
further in this discussion. MARGRIT  P.  SCHEID,  GIDEON  GOLDSTEIN,  AND  EDWARD  A.  BOYSE  1741 
There are no noteworthy differences between induction of these two popula- 
tions  in  regard  to  (a)  kinetics,  (b)  dependence  on  temperature  and  protein 
synthesis,  (c) activation by cAMP,  and  (d) inhibition by cGMP.  The opposite 
inductive effects of cAMP and cGMP were corroborated by the use of pharma- 
cological agents that raise or lower the levels of intracellular cyclic nucleotides. 
In contrast, a  third induction assay,  which monitors acquisition of the PC + 
surface phenotype, indicates that this differentiative step, the last known for B 
cells, is initiated by cGMP and inhibited by cAMP. 
Induction  of  PC  is  also  inhibited  by  thymopoietin,  signifying  that  the 
inductive selectivity of thymopoietin is not due to restriction of its receptors to 
the T lineage cells. Rather it seems that receptors for thymopoietin occur also 
on PC-inducible and other B cells, although in this case geared biochemically to 
inhibition rather than expression of  the succeeding gene program. This suggests 
a role for thymopoietin in the coordinated interregulation of  lymphocyte classes, 
in addition to its better-known function as the thymic inducer of prothymocytes. 
Present data  conform to  a  general  scheme in  which  the  cyclic nucleotides 
cAMP and cGMP, and agents that affect intracellular levels of these mediators, 
influence  reciprocally the  early  and  late  (functional)  phases  of lymphocyte 
differentiation  as  a  whole,  while  thymopoietin  influences  reciprocally  the 
differentiation of the B and T classes of lymphocyte. 
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